Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes

被引:106
作者
Lamhamedi-Cherradi, SE
Zheng, SJ
Tisch, RM
Chen, YH
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA
关键词
D O I
10.2337/diabetes.52.9.2274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of tumor cells but not most normal cells. Its roles in normal nontransformed tissues are not clear. To explore the potential roles of TRAIL in type I diabetes, we examined the consequences of TRAIL blockade or TRAIL deficiency in two animal models of autoimmune diabetes. In the first model, NOD mice received an injection of a soluble TRAIL receptor to block TRAIL function. This significantly accelerated the diabetes and increased the degree of autoimmune inflammation in both pancreatic islets and salivary glands. The GAD65-specific immune responses were also significantly enhanced in animals that received the soluble TRAIL receptor. In the second model, we treated normal and TRAIL-deficient C57BL/6 mice with multiple low-dose streptozotocin to induce diabetes. We found that both the incidence and the degree of islet inflammation were significantly enhanced in TRAIL-deficient animals. On the basis of these observations, we conclude that TRAIL deficiency accelerates autoimmune diabetes and enhances autoimmune responses.
引用
收藏
页码:2274 / 2278
页数:5
相关论文
共 30 条
[21]   Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus [J].
Rabinovitch, A ;
Suarez-Pinzon, WL .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (08) :1139-1149
[22]   Effector lymphocytes in autoimmunity [J].
Santamaria, P .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (06) :663-669
[23]  
SCHNEIDER P, 2002, J BIOL CHEM, V3, P3
[24]   Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes [J].
Simon, AK ;
Williams, O ;
Mongkolsapaya, J ;
Jin, B ;
Xu, XN ;
Walczak, H ;
Screaton, GR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) :5158-5163
[25]   Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression [J].
Song, KM ;
Chen, YG ;
Göke, R ;
Wilmen, A ;
Seidel, C ;
Göke, A ;
Hilliard, B ;
Chen, YH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (07) :1095-1103
[26]  
Thomas WD, 1998, J IMMUNOL, V161, P2195
[27]   TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL [J].
Walczak, H ;
DegliEsposti, MA ;
Johnson, RS ;
Smolak, PJ ;
Waugh, JY ;
Boiani, N ;
Timour, MS ;
Gerhart, MJ ;
Schooley, KA ;
Smith, CA ;
Goodwin, RG ;
Rauch, CT .
EMBO JOURNAL, 1997, 16 (17) :5386-5397
[28]   Identification and characterization of a new member of the TNF family that induces apoptosis [J].
Wiley, SR ;
Schooley, K ;
Smolak, PJ ;
Din, WS ;
Huang, CP ;
Nicholl, JK ;
Sutherland, GR ;
Smith, TD ;
Rauch, C ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1995, 3 (06) :673-682
[29]  
Wu GS, 1999, CANCER RES, V59, P2770
[30]   Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells [J].
Zamai, L ;
Ahmad, M ;
Bennett, IM ;
Azzoni, L ;
Alnemri, ES ;
Perussia, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2375-2380